Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NASDAQ:NXL

Nexalin Technology Q3 2026 Earnings Date & Estimates

Nexalin Technology logo
$1.71 -0.15 (-8.06%)
Closing price 04:00 PM Eastern
Extended Trading
$1.72 +0.01 (+0.70%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nexalin Technology is estimated to report Q3 2026 earnings on Friday, November 13, 2026. The conference call is scheduled for November 11, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Nexalin Technology in Q3 2026

Nexalin Technology is expected to post earnings of -$2.91 per share on revenue of $75 thousand. In the same quarter a year earlier Nexalin Technology reported -$3.90 per share on revenue of $18.15 thousand. Nexalin Technology last reported on August 12, 2026, posting -$0.11 per share and beating the -$3.00 consensus estimate. Nexalin Technology has beaten the consensus EPS estimate in 2 of its last 6 quarters.

Consensus Estimates

Consensus EPS
-$2.91
Expected Revenue
$75 thousand
Prior-Year EPS
-$3.90
Prior-Year Revenue
$18.15 thousand
Expected Revenue Growth
+313.2%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.11 (Beat by +$2.89)
Last Quarter Revenue
$12.16 thousand
EPS Beat Rate
2 of last 6 quarters

Prepare for the Q3 2026 Call

Nexalin Technology Q3 2026 Earnings FAQ

Nexalin Technology (NASDAQ:NXL) is estimated to report Q3 2026 earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Nexalin Technology's Q3 2026 earnings conference call is scheduled for Wednesday, November 11, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Nexalin Technology to post earnings of -$2.91 per share for Q3 2026.

The consensus revenue estimate for Nexalin Technology is $75 thousand for Q3 2026.

Nexalin Technology Earnings Headlines

Nuix Launches Agentic AI in Nuix Neo with Audit Trail Built In
October 21, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/nuix-launches-agentic-ai-in-nuix-neo-with-audit-trail-built-in-302916134.html
Q3 EPS Forecast for Nexalin Technology Lowered by Analyst
October 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31126991
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
October 26 at 1:00 AM  |  Crypto 101 Media (Ad)
Nexalin Technology Regains Compliance With Nasdaq Minimum Bid Price Requirement; Stock Down
October 8, 2026  |  rttnews.comhttps://www.rttnews.com/3697601/nexalin-technology-regains-compliance-with-nasdaq-minimum-bid-price-requirement-stock-down.aspx
Nexalin Technology notifies Nasdaq compliance on minimum bid price
October 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4651344-nexalin-technology-notifies-nasdaq-compliance-on-minimum-bid-price
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377254/0/en/nexalin-technology-regains-compliance-with-nasdaq-minimum-bid-price-requirement-nasdaq-hearings-panel-grants-request-for-continued-listing.html
See More Nexalin Technology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nexalin Technology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nexalin Technology and other key companies, straight to your email.

About Nexalin Technology

Nexalin Technology (NASDAQ:NXL) is a medical device company focused on developing noninvasive neurostimulation technologies for mental health and neurological applications. Its products are designed to deliver cranial electrotherapy stimulation (CES), a form of electrical stimulation intended to influence brain activity without the use of pharmaceutical drugs or invasive procedures.

The company’s product portfolio includes the Gen-2 and Gen-3 Nexalin devices, which use proprietary waveform technology and electrodes placed on the head to administer treatment. Nexalin has described its technology as being developed for potential applications including anxiety, depression, insomnia, and other conditions involving mental and neurological health. The company continues to pursue clinical development, regulatory clearances, and commercialization of its devices.

Nexalin Technology was founded in the early 2000s and is based in Houston, Texas. The company has sought to expand the availability of its technology through healthcare providers, research collaborations, and distribution relationships in the United States and international markets. Its leadership includes Chief Executive Officer Mark White, who has been associated with the company’s development and commercialization efforts.

View Nexalin Technology Profile
Earnings Tools